JPH0121839B2 - - Google Patents
Info
- Publication number
- JPH0121839B2 JPH0121839B2 JP2738982A JP2738982A JPH0121839B2 JP H0121839 B2 JPH0121839 B2 JP H0121839B2 JP 2738982 A JP2738982 A JP 2738982A JP 2738982 A JP2738982 A JP 2738982A JP H0121839 B2 JPH0121839 B2 JP H0121839B2
- Authority
- JP
- Japan
- Prior art keywords
- acid
- sarcochenodeoxycholic
- bile
- chenodeoxycholic
- gallstone
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- YZYBIGOLMMAZFK-USDKYCQXSA-N 2-[[(4r)-4-[(3r,5s,7r,8r,9s,10s,13r,14s,17r)-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]pentanoyl]-methylamino]acetic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)N(C)CC(O)=O)C)[C@@]2(C)CC1 YZYBIGOLMMAZFK-USDKYCQXSA-N 0.000 claims description 18
- 229960001091 chenodeoxycholic acid Drugs 0.000 description 12
- 208000001130 gallstones Diseases 0.000 description 12
- RUDATBOHQWOJDD-UHFFFAOYSA-N (3beta,5beta,7alpha)-3,7-Dihydroxycholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)CC2 RUDATBOHQWOJDD-UHFFFAOYSA-N 0.000 description 11
- RUDATBOHQWOJDD-BSWAIDMHSA-N chenodeoxycholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)CC1 RUDATBOHQWOJDD-BSWAIDMHSA-N 0.000 description 11
- SMEROWZSTRWXGI-UHFFFAOYSA-N Lithocholsaeure Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)CC2 SMEROWZSTRWXGI-UHFFFAOYSA-N 0.000 description 8
- 210000000941 bile Anatomy 0.000 description 8
- SMEROWZSTRWXGI-HVATVPOCSA-N lithocholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)CC1 SMEROWZSTRWXGI-HVATVPOCSA-N 0.000 description 8
- FSYKKLYZXJSNPZ-UHFFFAOYSA-N sarcosine Chemical compound C[NH2+]CC([O-])=O FSYKKLYZXJSNPZ-UHFFFAOYSA-N 0.000 description 8
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 239000003613 bile acid Substances 0.000 description 6
- 230000037213 diet Effects 0.000 description 6
- 235000005911 diet Nutrition 0.000 description 6
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- 239000003858 bile acid conjugate Substances 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 108010077895 Sarcosine Proteins 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 201000001883 cholelithiasis Diseases 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 210000003608 fece Anatomy 0.000 description 3
- 210000000936 intestine Anatomy 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 229940043230 sarcosine Drugs 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- BHQCQFFYRZLCQQ-UHFFFAOYSA-N (3alpha,5alpha,7alpha,12alpha)-3,7,12-trihydroxy-cholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 BHQCQFFYRZLCQQ-UHFFFAOYSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 239000004380 Cholic acid Substances 0.000 description 2
- 108010000231 Choloylglycine hydrolase Proteins 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- WBWWGRHZICKQGZ-UHFFFAOYSA-N Taurocholic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(=O)NCCS(O)(=O)=O)C)C1(C)C(O)C2 WBWWGRHZICKQGZ-UHFFFAOYSA-N 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 description 2
- 229960002471 cholic acid Drugs 0.000 description 2
- 235000019416 cholic acid Nutrition 0.000 description 2
- KXGVEGMKQFWNSR-UHFFFAOYSA-N deoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 KXGVEGMKQFWNSR-UHFFFAOYSA-N 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 2
- WBWWGRHZICKQGZ-GIHLXUJPSA-N taurocholic acid Chemical compound C([C@@H]1C[C@H]2O)[C@@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@@H]([C@@H](CCC(=O)NCCS(O)(=O)=O)C)[C@@]2(C)[C@H](O)C1 WBWWGRHZICKQGZ-GIHLXUJPSA-N 0.000 description 2
- 238000004809 thin layer chromatography Methods 0.000 description 2
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 241000193403 Clostridium Species 0.000 description 1
- 101710090058 Conjugated bile acid hydrolase Proteins 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 238000011047 acute toxicity test Methods 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 210000000013 bile duct Anatomy 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 231100000315 carcinogenic Toxicity 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 150000001801 chenodeoxycholic acids Chemical class 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 210000001198 duodenum Anatomy 0.000 description 1
- 238000000921 elemental analysis Methods 0.000 description 1
- 230000010235 enterohepatic circulation Effects 0.000 description 1
- RIFGWPKJUGCATF-UHFFFAOYSA-N ethyl chloroformate Chemical compound CCOC(Cl)=O RIFGWPKJUGCATF-UHFFFAOYSA-N 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 230000031891 intestinal absorption Effects 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 229960003080 taurine Drugs 0.000 description 1
- IMFACGCPASFAPR-UHFFFAOYSA-N tributylamine Chemical compound CCCCN(CCCC)CCCC IMFACGCPASFAPR-UHFFFAOYSA-N 0.000 description 1
- 231100000691 up-and-down procedure Toxicity 0.000 description 1
Landscapes
- Steroid Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2738982A JPS58146599A (ja) | 1982-02-24 | 1982-02-24 | サルコケノデオキシコ−ル酸 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2738982A JPS58146599A (ja) | 1982-02-24 | 1982-02-24 | サルコケノデオキシコ−ル酸 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS58146599A JPS58146599A (ja) | 1983-09-01 |
| JPH0121839B2 true JPH0121839B2 (de) | 1989-04-24 |
Family
ID=12219698
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2738982A Granted JPS58146599A (ja) | 1982-02-24 | 1982-02-24 | サルコケノデオキシコ−ル酸 |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS58146599A (de) |
-
1982
- 1982-02-24 JP JP2738982A patent/JPS58146599A/ja active Granted
Also Published As
| Publication number | Publication date |
|---|---|
| JPS58146599A (ja) | 1983-09-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CZ289515B6 (cs) | Tetrazolové deriváty ľlučových kyselin a léčivo tyto deriváty obsahující | |
| US5583239A (en) | Antimicrobial sterol conjugates | |
| JPH0687884A (ja) | 胆汁酸誘導体、その製造方法および医薬としてのこれらの化合物の使用 | |
| Batta et al. | Substrate specificity of cholylglycine hydrolase for the hydrolysis of bile acid conjugates. | |
| JPH0717997A (ja) | タウロコラン酸の製造方法 | |
| LU82568A1 (fr) | Nouveaux dipeptides,leur preparation et les medicaments qui les contiennent | |
| JPH0121839B2 (de) | ||
| EP0060999A1 (de) | Galactopyranoside Verbindungen, Verfahren zu ihrer Herstellung und ihre Verwendung als Antigene oder Immunadsorbentien | |
| EP0551451A1 (de) | N-alkyl-tauroursodeoxycholsäure und ihre therapeutisch aktiven derivate, verfahren zu deren herstellung sowie pharmazeutische präparate davon | |
| JPS6312063B2 (de) | ||
| IL148404A (en) | Process for the preparation of 3-amino derivatives of bile acid | |
| WO1992004369A1 (en) | 5-aminosalicylic acid derivatives for the therapy of chronic inflammatory bowel diseases | |
| JPH0121838B2 (de) | ||
| LU82569A1 (fr) | Nouveaux tripeptides,leur preparation et les medicaments qui les contiennent | |
| CN112851740B (zh) | G蛋白偶联胆酸受体内源性配体衍生物及其制备方法和在抗肿瘤活性中的应用 | |
| US4388241A (en) | Bile acids | |
| US5693770A (en) | Process for the manufacture of 3-amino-substituted glycosylated bile acids | |
| US4404199A (en) | Salification products of cholic acids with trimethoxy-3,4,5-benzoic ester of 2-phenyl-2-dimenthylaminobutanol, having pharmacotherapeutic action, process for their preparation and therapeutic compositions containing them as active principle | |
| WO1994002503A1 (en) | Bile acid derivative and use thereof in therapy | |
| US3864365A (en) | Carbonic acid derivatives of estradiol and processes for their production | |
| CN101367859B (zh) | 脂肪酸胆汁酸偶合物及其医药用途 | |
| CA1096372A (fr) | Procede de preparation de nouveaux 2,2-dimethyl 19- nor steroides | |
| EP0100983A1 (de) | Steroidderivate mit choleretischer Wirkung, Verfahren zu ihrer Herstellung und therapeutische Zusammensetzungen die sie enthalten | |
| JPS6351156B2 (de) | ||
| JP3010173B2 (ja) | ジエチレントリアミン三酢酸化合物およびその製造法 |